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ABSTRACT
Epithelial ovarian cancer (EOC) spreads by direct dissemination of malignant cells and
multicellular clusters, known as spheroids, into the peritoneum followed by implantation and
growth on abdominal surfaces. Using a spheroid model system of EOC metastasis, we
discovered that Liver kinase B1 (LKB1), encoded by the STK11 gene, and its canonical substrate
AMP-activated protein kinase (AMPK) are activated in EOC spheroids, yet only LKB1 is
required for cell survival. We have now generated STK11-knockout cell lines using normal
human FT190 cells and three EOC cell lines, OVCAR8, HeyA8, and iOvCa147. STK11KO did
not affect growth and viability in adherent culture, but it decreased anchorage-independent
growth of EOC cells. EOC spheroids lacking LKB1 had markedly impaired growth and viability,
whereas there was no difference in normal FT190 spheroids. To test whether LKB1 loss affects
EOC metastasis, we performed intraperitoneal injections of OVCAR8-, HeyA8-, and iOvCa147STK11KO cells, and respective controls. LKB1 loss exhibited a dramatic reduction on tumour
burden and metastatic potential; in particular, OVCAR8-STK11KO tumours had evidence of
extensive necrosis, apoptosis and hypoxia. Interestingly, LKB1 loss did not affect AMPKα
phosphorylation in EOC spheroids and tumour xenografts, indicating that LKB1 signaling to
support EOC cell survival in spheroids and metastatic tumour growth occurs via other
downstream mediators. We identified the dual-specificity phosphatase DUSP4 as a commonly
upregulated protein due to LKB1 loss; indeed, DUSP4 knockdown in HeyA8-STK11KO cells
restored spheroid formation and viability. Our results strongly indicate that intact LKB1 activity
independent of downstream AMPK signaling is required during EOC metastasis.
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INTRODUCTION
Epithelial ovarian cancer (EOC) is a highly lethal malignancy in women since nearly all patients
are diagnosed with metastatic disease, at which point the 5-year survival rate is only 30% [1].
Standard-of-care for late-stage EOC has largely unchanged over 25 years and encompasses
aggressive cytoreductive surgery with combination carboplatin/paclitaxel chemotherapy. Most
patients initially respond to treatment, but recurrence and chemo-resistance is common and fatal
in most cases. Therefore, the development of novel approaches to impede metastasis and
recurrence of chemo-resistant disease will be paramount to improve outcomes for women
diagnosed with EOC [2].
A common symptom of advanced EOC is the accumulation of ascites within the peritoneal
cavity [3]. This ascites often harbors individual malignant cells or those existing as multicellular
aggregates, herein referred to as spheroids, the latter of which offer numerous selective
advantages in the context of metastatic dissemination [4]. EOC spheroids exhibit anoikis
resistance and possess an enhanced capacity to adhere to ECM and displace mesothelial cell
monolayers [3; 5; 6]. In addition, recent evidence indicates that EOC spheroids seed peritoneal
metastases that maintain the cellular heterogeneity of the primary tumour [7]. Thus, EOC
spheroids likely play a key role in efficient intraperitoneal metastasis.
We previously reported that Liver kinase B1 (LKB1; encoded by the STK11 gene) is
expressed in the majority of EOC cell lines and patient ascites-derived cells; importantly,
transient knockdown of STK11 in EOC cells results in reduced spheroid viability and increased
chemo-sensitization [8]. LKB1 is a ubiquitously-expressed, highly-conserved serine-threonine
kinase that commonly acts as the upstream kinase for AMP-activated protein kinase (AMPK),
primarily in regulating cell metabolism [9]. The LKB1-AMPK signaling axis functions as a
4
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sensor of energy status in the cell and enables adaptation to conditions that deplete intracellular
ATP. Decreased ATP and the corresponding increase in AMP favors phosphorylation and
activation of AMPK by LKB1, resulting in the coordinated downregulation of anabolic pathways
and upregulation of catabolic pathways to restore energy homeostasis [10].
LKB1 is often described as having tumour suppressor-like activity since specific cancers
feature somatic alterations in the LKB1-encoding gene STK11 [11-13] or have decreased LKB1
protein expression [14; 15]. In addition, germline inactivating mutations in STK11 have been
implicated in Peutz-Jeghers syndrome (PJS) [16], which is characterized by the formation of
benign polyps in the gastrointestinal tract and an increased risk for several cancers [17]. LKB1
loss has also been implicated in EOC initiation [15; 18]; however, there is significant evidence
suggesting that LKB1 and its direct signaling partners function in context-dependent, protumorigenic capacities [8; 19-22].
To date, no studies have assessed the impact of LKB1 loss-of-function in mouse models of
cancer metastasis, such as late-stage EOC. In this study, we sought to determine how complete
LKB1 ablation in EOC cells would affect metastatic potential. We present evidence indicating
that LKB1 loss decreases anchorage-independent viability of EOC cells and reduces the longterm spheroid maintenance. In a similar fashion, LKB1 loss in three independent EOC cell lines
significantly reduced tumour burden and extended host survival in a xenograft mouse model of
peritoneal metastasis. Based on these findings, we propose that strategies targeting LKB1 or its
signaling partners would have therapeutic potential in metastatic EOC.
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RESULTS
LKB1 lacks tumour suppressor-like activity in EOC
We previously reported that LKB1 protein is expressed in EOC tumour samples, and that
transient STK11 knockdown decreases EOC spheroid viability and chemo-resistance, suggesting
that LKB1 or its signaling partners might represent viable therapeutic targets in EOC [8].
Therefore, we sought to investigate how sustained LKB1 loss would affect tumourigenic and
metastatic potential in several different EOC cell lines. OVCAR8 (high-grade serous ovarian
cancer; HGSOC) and HeyA8 (poorly-differentiated ovarian cancer) cells form robust spheroids
as well as aggressive tumour growth in immune-compromised mice, and therefore represent two
EOC cell lines with which to test our hypothesis regarding LKB1 function. The iOvCa147 cell
line was derived by our group from the ascites of a heavily-treated HGSOC patient [23]. This
cell line forms less dense yet viable spheroids, and establishes ascites and tumours in NOD/SCID
mice with longer latency as compared with OVCAR8 and HeyA8 cells. We used CRISPR/Cas9based genome editing to generate stable cell lines lacking LKB1 expression: OVCAR8STK11KO, HeyA8-STK11KO, and iOvCa147-STK11KO, as well as one immortalized human
fallopian tube secretory epithelial cell line (FT190-STK11KO) for comparison. Complete
ablation of LKB1 expression was confirmed in each STK11KO cell line (Figure 1A). Under
standard adherent culture conditions, STK11KO cell lines resembled parental controls with
respect to morphology; iOvCa147-STK11KO cells were the notable exception and had a spindleshaped appearance compared to controls (Supplemental Figure S1). Stable LKB1 loss in our
newly-derived STK11KO cell lines did not affect proliferation since doubling time was
unchanged compared with parental cell lines (Figure 1B).
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It is well-established that the majority of HGSOC likely originate in the secretory
epithelium of the distal fimbriae of the fallopian tube [24-26], and mouse models also support
this as a primary cell-of-origin in this disease [27-29]. Two reports have implied that loss of
LKB1 expression may be involved in the development of HGSOC [15; 18] whereas we have
alternative conflicting data demonstrating that LKB1 is in fact expressed and functional in latestage EOC [8]. If LKB1 has tumour-suppressive properties in EOC, then STK11 knockout should
enhance normal FT190 cell clonogenicity in both anchorage-dependent and -independent
conditions. We performed clonogenic assays using each line harboring LKB1 loss to determine
whether anchorage-dependent replicative potential would be affected by loss of LKB1 in FTE
and EOC cells. We found that LKB1 loss significantly decreased clonogenic potential in FT190
cells, but not in any EOC cell lines tested (Supplemental Figure S2).
Since anchorage-independence is a common feature of transformed cells and critical to
EOC metastasis, we determined how LKB1 loss would affect anchorage-independence in normal
FTE and transformed EOC cells. In contrast to the results from adherent clonogenic assays, loss
of LKB1 significantly decreased soft agar colony number and colony size in HeyA8 cells
(Figure 1C & D); OVCAR8-STK11KO soft agar colony number was not different from parental
controls, however colony size was significantly decreased (Figure 1C & D). The iOvCa147 cell
line has a very poor colony-forming capacity in soft agar and were thus not tested by this assay.
Furthermore, FT190 cells, which have been immortalized due to p53 and pRB inactivation by
SV40 large T antigen [30], were unable to establish any colonies in soft agar with or without
intact LKB1 (data not shown). These results suggest that LKB1 does not possess overt tumour
suppressive activity, but may be required for aggressive EOC cell growth or viability when in
suspension.
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LKB1 is required in EOC spheroids to maintain cell viability
Spheroids are frequently present in the peritoneal ascites of EOC patients, and facilitate
peritoneal metastasis since they exhibit anoikis resistance, adhere to mesothelial cell monolayers
[3; 5], and help to establish peritoneal metastases [7]. We have demonstrated previously that
decreased LKB1 expression by transient STK11 knockdown has little to no effect on the growth
and viability of adherent proliferating EOC cells, yet viability is reduced in spheroids [8]. Thus,
we sought to determine how sustained loss of LKB1 would affect FTE and EOC spheroid
viability. We cultured FTE and EOC cells in ultra-low attachment (ULA) culture plates to force
cells into suspension (Figure 2A). LKB1 loss significantly decreased the number of viable cells
for all EOC cell lines tested (Figure 2B), and the proportion of dead iOvCa147-STK11KO cells
significantly increased, indicating that LKB1 is required for maximal EOC spheroid viability in
this in vitro model of metastasis. Normal FT190 cells exhibited rapid attrition in spheroid culture
(Figure 2A) with even further loss in cell viability due to LKB1 loss (Figure 2B), indicating
again that LKB1 loss does not possess tumour suppressor-like activity when FTE cells are
deprived of attachment to a substratum. Long-term spheroid culture of HeyA8 and OVCAR8
cells yielded an overt decrease in growth and viability due to LKB1 loss (Supplementary
Videos), and this was especially pronounced when spheroids were maintained for up to 21 days
(Figure 2C). This latter result provided strong in vitro evidence suggesting that tumour-forming
and metastatic potential of EOC cells in vivo may be blunted by loss of LKB1.
LKB1 is required to maintain EOC metastatic potential
The results of our in vitro studies indicate that LKB1 is required for both anchorageindependence and spheroid viability in EOC cells. Since spheroids play an important role in
EOC metastasis, we sought to determine the effect of LKB1 loss in an in vivo xenograft model of
8
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peritoneal metastasis. EOC cells are injected directly into the peritoneal space of
immunodeficient host mice to mimic metastasis, where tumour pathology and pattern of
dissemination are similar to late-stage disease in patients [31]. We hypothesized that stable
LKB1 ablation in EOC cells would decrease metastatic potential in vivo.
We found that survival was extended in hosts for all three STK11KO cell lines when
compared with parental cell lines (Figure 3A). Compared to parental control hosts, median
survival was 48.5% longer for OVCAR8-STK11KO hosts (78 d versus 52 d; log-rank test, p =
0.0005), but only 17.1% longer for HeyA8-STK11KO hosts, which approached statistical
significance (51 d versus 41 d; log-rank test, p = 0.1105). Median survival for iOvCa147STK11KO hosts was undetermined since most mice survived until study completion, yet survival
was significantly longer than the parental control group (log-rank test, p = 0.0015).
Frequency of ascites accumulation was decreased in OVCAR8-STK11KO relative to
OVCAR8 injected mice, but overall dissemination patterns were similar, indicating that
metastatic trajectory was unchanged by LKB1 loss (Figure 3B and Supplementary Table S1).
Macroscopic tumour burden in OVCAR8-STK11KO injected hosts was significantly decreased
compared to OVCAR8 cells (Figure 3B). In mice injected with HeyA8-STK11KO cells and
HeyA8 controls, we observed an altered pattern of tumour dissemination associated with LKB1
loss. HeyA8-STK11KO-injected hosts exhibited a thin layer of tumour cells adherent to the
peritoneal wall, and little evidence of solid tumour lesions at other sites (Figure 3B and
Supplementary Table S1). In contrast, HeyA8-injected hosts had several large and solitary solid
tumour masses at the omentum and lower peritoneal cavity, often adherent to the intestine and
uterus (Figure 3B and Supplementary Table S1). This resulted in a total tumour burden that
was significantly reduced in HeyA8-STK11KO injected mice as compared with HeyA8 controls
9
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(Figure 3C). Sustained LKB1 loss was confirmed by immunoblotting of protein lysates from
excised OVCAR8- and HeyA8-STK11KO tumours (Figure 3D).
Similar to our in vitro spheroid assays, we observed the most striking effects of LKB1 loss
in the iOvCa147 cell line, which was originally generated from the ascites of a high-grade serous
ovarian cancer patient by our group [23]. In line with the extended survival of iOvCa147STK11KO hosts (Figure 3A), peritoneal colonization was substantially diminished, with most
mice exhibiting little evidence of macroscopically-observable peritoneal tumours upon necropsy
(Figure 3B). In contrast to iOvCa147-STK11KO hosts, mice injected with iOvCa147 parental
control cells exhibited peritoneal tumours at multiple sites, with particularly frequent
colonization at the omentum, peritoneal wall and diaphragm. Since most iOvCa147-STK11KO
mice failed to develop tumours, we did not measure overall tumour burden in this cohort.
Histological analysis indicated that OVCAR8-STK11KO tumour nodules frequently
contained large necrotic regions, and immunohistological staining revealed that Ki-67-positive
cells were frequently restricted to the periphery of tumour nodules with a core of cleaved caspase
3-positive apoptotic cells (Figure 4A). Compared to parental OVCAR8 controls, these highlynecrotic/apoptotic OVCAR8-STK11KO tumours had increased carbonic anhydrase 9 protein
expression (Figures 4B & C), which is indicative of elevated hypoxia in tumours [32]. In
contrast, enhanced necrosis and apoptosis was not observed in HeyA8-STK11KO tumour
xenografts, however there appeared to be fewer Ki-67 positive cells compared with HeyA8
tumours (Figure 4A). Very few iOvCa147-STK11KO hosts developed any tumours (Figure 3A
and Supplementary Table S1). However, histologic analysis of a single iOvCa147-STK11KO
lesion revealed thinly-deposited EOC cells with papillary features that were not evident in the
solid tumours arising in iOvCa147 controls (Figure 4A).
10
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Notably, the significant decrease in in vivo metastatic potential for all three STK11KO
EOC cell lines corresponded very well with our in vitro results using the spheroid model of
metastasis (Figure 2). Furthermore, in cases where ascites was recovered from host mice, we
observed the presence of multicellular aggregates that resembled the morphology of spheroids
generated in vitro (Supplemental Figure S3). This indicates that spheroid biology in our in vitro
model recapitulates the phenotype of spheroids formed in an established in vivo model of EOC
metastasis.
LKB1-independent AMPK phosphorylation in EOC cells, spheroids and xenograft
tumours
We demonstrated previously that both LKB1 and phosphorylated AMPKα are coordinately
upregulated in EOC spheroids [8], suggesting that LKB1-AMPK signaling is activated during
EOC metastasis. Since LKB1 is commonly described as the major upstream kinase responsible
for phosphorylation of AMPKα at Thr172 [9], we expected that phospho-AMPKα would be
substantially decreased or ablated in STK11KO spheroids relative to parental controls. Instead,
we found that phospho-AMPKα Thr172 was maintained in spheroids for all STK11KO cell lines
tested (Figure 5A), indicating that in FTE and EOC spheroids AMPKα is phosphorylated by one
or more other kinases independently of LKB1.
Ca(2+)/calmodulin-dependent kinase kinase-beta (CAMKK2) is one principal alternative
AMPK upstream kinase [33], and cell detachment can rapidly induce phospho-AMPKα at T172
in a CAMKK2-dependent manner in breast cancer cells [34]. Therefore, we treated FT190STK11KO, OVCAR8-STK11KO, and iOvCa147-STK11KO spheroids and parental cell line
controls with STO-609, a potent cell-permeable inhibitor of CAMKK2 [35]. STO-609
substantially decreased phospho-AMPKα in adherent cells and spheroids for all cell lines tested
11
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(Figure 5B), indicating that CAMKK2 is likely the major activating kinase for AMPKα in FTE
and EOC cells, whether LKB1 is present or not. Importantly, analysis of tumour xenografts
revealed that phospho-AMPKα was unaffected by loss of LKB1, also (Figure 5C & D). Indeed,
LKB1 loss had no effect on OVCAR8 cells when subjected to several metabolic stressors—
glucose deprivation, serum starvation, mitochondrial inhibition, and AMP mimetic treatment—
which act through AMPK activity (Supplemental Figure S4). Taken together, these results
imply that any of our observed phenotypic effects due to LKB1 loss in FTE and EOC cells and
spheroids, and during EOC metastasis in mice, are most likely AMPK-independent.
DUSP4 is upregulated due to sustained LKB1 loss
Since it appeared that AMPK was not mediating the phenotypic changes in EOC spheroids and
tumours due to LKB1 loss, we sought to discover other potential effectors. To do so, we
performed reverse phase protein array (RPPA) analysis comparing STK11KO knockout cells
grown in adherent and spheroid culture using both OVCAR8 and HeyA8 cells. From this data,
we observed distinct differences in protein expression between the OVCAR8 and HeyA8
spheroids due to LKB1 loss (Figure 6A and Supplementary Table S2), which may reflect the
differences seen in spheroid culture and xenograft experiments between these two distinct EOC
cell lines. However, one protein that was consistently increased due to LKB1 loss in both
adherent cells and even more so in spheroids was dual-specificity phosphatase 4 (DUSP4). We
observed a 1.86-2.06-fold increase in OVCAR8-STK11 adherent cells and 1.76-2.57-fold
increase in spheroid culture; in HeyA8-STK11KO cells, DUSP4 protein was elevated by 2.372.76-fold in adherent and 2.84-3.12-fold in spheroids. We confirmed this increase in DUSP4
protein expression among all three EOC cell lines where LKB1 was ablated (Figure 6B). In
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addition, DUSP4 was increased significantly in OVCAR8-STK11KO xenografts as compared
with tumours derived from OVCAR8 cells (Figure 6C and 6D).
DUSP4 is a dual-specificity phosphatase that typically targets several MAPKs to decrease
their phosphorylation state and thus downstream signaling activity [36]. To this end, we
performed immunoblot analysis of phosphorylated ERK, JNK and p38 among the three EOC cell
lines lacking LKB1 as compared with controls. Interestingly, phospho-ERK1/2 was consistently
decreased in EOC cells upon spheroid culture, however levels of phospho-p38 and phospho-JNK
(p54 and p46) were either unchanged or different among the three cell lines (Supplementary
Figure S5). Levels of phosphorylated ERK, JNK and p38, however, yielded no change due to
LKB1 loss even though DUSP4 protein is universally increased in these cell lines. To further
investigate whether upregulation of DUSP4 protein may impact the spheroid phenotype (i.e.,
reduced formation potential and cell viability) due to LKB1 loss, we performed transient DUSP4
knockdown in HeyA8 and HeyA8-STK11KO cells (Figure 6E) and subsequently formed
spheroids. We observed a restoration of intact spheroid formation by DUSP4 knockdown in
HeyA8-STK11KO spheroids (Figure 6F), as well as increased cell viability to levels similar to
control HeyA8 spheroids (Figure 6G). Therefore, we speculate that DUSP4 is at least one
protein mediating the reduced metastatic potential due to LKB1 loss in our in vitro spheroid
model, and potentially decreased tumour formation and metastasis in vivo.

DISCUSSION
Peritoneal metastasis in EOC is often associated with the accumulation of malignant ascites,
which contains spheroids that play a key role in disease progression [3]. We previously reported
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that EOC cells require LKB1 to maintain spheroid viability and chemo-resistance [8]. Given the
functional relevance of spheroids in EOC metastasis [3; 5-7], targeting LKB1 or its signaling
partners in metastatic EOC may have therapeutic value. Herein, we now present additional
evidence that EOC cells require LKB1 for maximal metastatic potential and add to the body of
literature indicating that LKB1 can function in a pro-oncogenic capacity to promote disease
progression. Based on our findings, and those of others, we propose that LKB1 or its AMPKindependent signaling partners may represent therapeutic vulnerabilities in metastatic EOC.
In the context of cancer, LKB1 has been commonly described as possessing tumour
suppressor-like function. STK11 is frequently deleted in non-small cell lung cancer (NSCLC)
[37], and somatic nonsense mutations in STK11 occur with high frequency in primary lung
carcinomas and lung cancer cell lines [12], as well as in 20% of cervical cancer [13] and
melanoma [11]. Loss of LKB1 in the ovarian surface epithelium has been linked to papillary
serous ovarian cancer in a mouse model [18]. LKB1 protein expression is decreased in HGSOC
relative to normal FTE tissue; however, this study also found that genomic loss of both STK11
alleles was associated with improved patient survival [15]. In fact, our previous report [8]
demonstrated that LKB1 expression is maintained in late-stage EOC and is required for cell
survival in spheroids and promotes platinum resistance. Given that FTE cells are the most likely
cell-of-origin in HGSOC, we had the direct ability to determine whether LKB1 may act as a
tumour suppressor in FT190 cells with its loss resulting in their oncogenic transformation.
However, we found that neither cell proliferation, nor colony formation, nor anchorageindependence, nor spheroid viability and growth were increased due to STK11 gene inactivation.
Since FT190 cells are immortalized by expression of SV40 large T antigen [30], our results also
indicate that the combination of p53 and pRb inactivation with LKB1 loss is insufficient for
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malignant transformation of FTE cells. Given the report suggesting decreased LKB1 protein
expression in pre-malignant STIC lesions and primary serous ovarian tumours [15], we propose
that LKB1 re-expression and its pro-metastatic effects are manifest at later steps in ovarian
tumorigenesis after initial neoplastic transformation.
A growing body of evidence suggests that LKB1 can function in context-dependent, protumorigenic capacities. In line with its role in metabolism, deficiencies in LKB1-AMPK
signaling sensitize some cancer cells to energy stress. LKB1-deficient NSCLC cells are more
sensitive to the mitochondrial complex I inhibitor phenformin compared to NSCLC cells with
intact LKB1 [38], and AMPK is required in A549 lung cancer cells for survival under glucosedeprived culture conditions [20]. However, LKB1 may also promote oncogenic potential in ways
that are not directly linked to the energy stress response. Expression of LKB1 protein is
associated with poor patient prognosis in hepatocellular carcinoma, and ectopic expression of
LKB1 in Hep3B cells increases tumour xenograft growth [39]. Similar to our study of EOC cells,
STK11 knockdown decreases spheroid formation and clonogenicity of MCF-7 cells, indicating
that LKB1 can enhance anchorage-independence and replicative potential in breast cancer cells
[22]. We have not yet elucidated the mechanisms by which LKB1 promotes metastatic potential
of EOC cells; however, our data provide additional evidence to support its pro-tumorigenic role
in yet another cancer-specific context.
During metastasis, cancer cells must overcome significant hurdles to maintain viability and
seed the formation of secondary tumours. Enhanced anoikis resistance is associated with greater
aggressiveness and tumorigenicity in in vivo models of EOC [40]. We found that LKB1 loss had
little effect on EOC cell growth under standard adherent culture conditions, while having a clear
negative impact on EOC cell viability in suspension. Our findings imply that LKB1 supports
15
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anoikis resistance and anchorage-independence in EOC cells through mechanisms that do not
involve AMPK. We previously reported that phosphorylation of AMPKα at Thr172, which is
required for its full catalytic activity [41], is induced upon EOC spheroid formation [8]. Herein,
we show that despite LKB1 loss, phospho-AMPKα levels in FTE and EOC spheroids remain
elevated, which implies AMPKα activation occurs independently of LKB1 in our spheroid
system. One such alternative kinase is CAMKK2 [33], which has been implicated in cell
detachment-induced phosphorylation of AMPKα in several breast cancer cell lines [34]. Using
STO-609, we provide evidence that AMPKα phosphorylation in FTE and EOC spheroids is
largely mediated by CAMKK2. In fact, CAMKK2 inhibition using STO-609 does not affect
EOC spheroid cell viability (Laski and Shepherd, unpublished), which corroborates our previous
finding that knockdown of PRKAA1/2 encoding AMPK catalytic subunits[8]. Thus, we conclude
that phospho-AMPK is induced via CAMKK2 in EOC spheroids, but that AMPK activity is
dispensable for maintaining spheroid cell viability in the context of LKB1 activity.
While AMPKα is often described as the primary cell stress signaling mediator downstream
of LKB1, we demonstrate that essential LKB1 functions in EOC metastasis are AMPKindependent. LKB1 is known to phosphorylate at least 12 substrates that are similar in structure
to AMPK, collectively termed AMPK-related kinases. Broadly, these kinases can regulate cell
polarity, migration, and metabolism in specific cell contexts [42]. Salt-inducible kinases SIK2
and SIK3 may be required in HGSOC metastasis, but their dependence on LKB1 in this disease
is unknown [43-45]. AMPK-related kinase ARK5/NUAK1 has been reported to be
overexpressed in EOC and implicated in the regulation of EMT [46]. In line with this, NUAK1
expression in EOC is associated with poor patient prognosis [47]. Our group is currently
pursuing additional NUAK1 functions as a substrate of LKB1 in metastatic EOC. Elucidation of
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these downstream mediators will likely be of clinical relevance since they may represent more
specific and suitable therapeutic targets in metastatic EOC than LKB1 itself.
We postulate that EOC cells are adaptively reprogrammed to handle abrogated stress
signaling due to sustained LKB1 loss. DUSP4 is commonly increased in NSCLC tumours
possessing STK11 loss-of-function mutations. Kaufman et al [48] identified an upregulated 16gene expression signature, which included DUSP4, in LKB1-deficient NSCLC cells likely due to
an altered oxidative stress response mediated by NRF2. We postulate that there is a similar
dysregulated response to oxidative stress and hypoxia in the absence of LKB1 function in EOC
spheroids and tumour xenografts. This could explain our observation of elevated hypoxia in
OVCAR8-STK11KO xenograft tumours correlating with increased DUSP4 expression, perhaps
resulting from chronic stress due to LKB1 loss in this cell line. It would be intriguing to study
whether LKB1 signaling is required in response to tumour hypoxia and oxidative stress to
regulate a downstream transcriptional network and mitigate these key metabolic stresses in
cancer.
While LKB1 may act as a tumour suppressor in other cancers, we have provided additional
evidence that LKB1 clearly possesses important functions in a pro-metastatic capacity during
EOC progression. Consistent with the established notion that three-dimensional spheroids
contribute to EOC dissemination, we have demonstrated that intact LKB1 is required in both in
vitro spheroid and in vivo xenograft models of metastatic disease. Overall, we provide supportive
evidence that LKB1 or its direct signaling partners represent viable therapeutic targets in
metastatic EOC.
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MATERIALS AND METHODS
Cultured cell lines
OVCAR8 and HeyA8 cell lines were cultured in RPMI-1640 (Wisent). FT190 and iOvCa147
cell lines were cultured in DMEM/F12 (Life Technologies). For all cell lines, growth medium
was supplemented with 10% FBS. OVCAR8 and HeyA8 cells were obtained from the American
Type Culture Collection and iOvCa147 cells were generated by us as described previously [23].
The immortalized human fallopian tube secretory epithelial cell line FT190 [30] was provided by
R. Drapkin (University of Pennsylvania). All cell lines were authenticated by short tandem
repeat analysis performed by The Centre for Applied Genomics (The Hospital for Sick Children,
Toronto, ON, Canada), and routinely tested for mycoplasma using the Universal Mycoplasma
Detection Kit (30-1012K, ATCC) or as performed by IDEXX BioResearch (Columbia, MO,
USA) prior to xenograft experiments.
Generation of STK11KO cell lines
The 20-nucleotide guide sequence targeting the STK11 gene 5’-AGCTT GGCCC GCTTG
CGGCG-3’ was selected using CRISPR Design Tool (http://tools.genome-engineering.org).
Complementary oligonucleotides 5’-CACCG AGCTT GGCCC GCTTG CGGCG-3’ and 5’AAACC GCCGC AAGCG GGCCA AGCTC-3’ (Sigma-Genosys) were annealed and ligated
into the BbsI-digested restriction endonuclease site of pSpCas9(BB)-2A-Puro plasmid (gift from
Dr. F. Dick, Western University) as per the protocol described in Ran et al. [49] to generate the
pSpCas9-sgSTK11 plasmid. Cells were transfected with pSpCas9-sgSTK11 plasmid using
LipofectAMINE 2000 (Invitrogen) according to manufacturer’s instructions, followed by
treatment with 1 μg/mL puromycin for one day. After growth recovery, limiting dilution
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subcloning of potential STK11-knockout cells was performed and confirmation of STK11
knockout by western blotting for LKB1 expression. A minimum of five clones lacking LKB1
protein expression were positively identified and subsequently mixed in equal ratios to generate
the STK11KO cell line populations.
Antibodies and reagents
Antibodies against LKB1 (#3050S), phospho-AMPKα (T172) (#2535S), AMPKα (#5832S),
phospho-p44/42 ERK (T202/Y204) (#9101S), phospho-JNK (T183/Y185) (#4668P), phosphop38 (T180/Y182) (#4511S), and DUSP4 (#5149S) were purchased from Cell Signaling (Danvers,
MA) and used at 1:1000 in 5% bovine serum albumin (BSA)/TBS-T. Antibody against CA9
(AF2188; 1 μg/mL) was purchased from R&D Systems (Minneapolis, MN). Antibody against
tubulin (T5168; 1:8000) and vinculin (V9264; 1:50 000) were purchased from Sigma (St. Louis,
MO). Antibody against vinculin was purchased from HRP-conjugated antibodies against mouse
IgG (NA931V; 1:10 000) and rabbit IgG (NA934V; 1:10 000) were purchased from Sigma.
Immunohistochemistry was performed by Molecular Pathology (Robarts Research Institute,
London ON, Canada); antibodies against Ki67 and cleaved caspase-3 were purchased from
Abcam and used according to Molecular Pathology standard protocols. Oligomycin A (#11342)
and AICAR (#10010241) were purchased from Cayman Chemical Company (Ann Arbor, MI,
USA); STO-609 (#73862) was purchased from STEMCELL Technologies (Vancouver, BC,
Canada).
Immunoblot analysis
Isolation of protein lysates and western blotting were performed as described previously[8].
Doubling time determination in adherent culture
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Cells were seeded into 96-well adherent culture plates at a density of 1000 cells per well. Phasecontrast images were captured at 3-hour intervals for a total of 96 hours and confluence was
measured using the IncuCyte Zoom imaging platform. Doubling time was determined by fitting
an exponential growth curve to the confluence-over-time data (GraphPad Prism 6.05).
Clonogenic assays
Cells were seeded at specific cell densities then fixed and stained when cells formed well-defined
colonies with minimal overlap. OVCAR8 and OVCAR8-STK11KO cells: 250 cells/35-mm well,
8 days; iOvCa147 and iOvCa147-STK11KO cells: 1000 cells/35-mm well, 8 days; HeyA8 and
HeyA8-STK11KO cells: 2500 cells/10-cm plate, 14 days; FT190 and FT190-STK11KO cells:
1000 cells/10-cm plate, 12 days. Cells were fixed and stained using the Protocol Hema 3 staining
kit (Fisher Scientific). Colony number and size were determined using the Fiji Is Just ImageJ
(Fiji) image processing software package [50]; the Trainable Weka Segmentation plugin [51]
was used to generate classifiers to segment images into stained colonies and background. Images
were converted into binary colour, “fill holes” and “watershed” functions were applied, and
pixel-to-distance scale was set using the culture vessel diameter. Colony number and area were
determined using the “analyze particles” function to outline each colony as a region of interest
and provide colony counts.
Soft agar assays
EOC cells were suspended at a density of 25 000 cells/1.5 mL in medium supplemented with 10%
FBS and 1% melted soft agar; this suspension was added to each well containing solidified 2%
agar. Additional growth medium was then added to each well, and plates were incubated for 14
days. Images of random fields of view were captured at 25x magnification using a Leica DMI
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4000B inverted microscope. Colony number and size were determined using the Fiji image
processing software package as described above.
Spheroid viability assay
Cells were seeded into 24-well ULA cluster plates (50 000 cells per well in a volume of 1 mL).
At the specified time points, the entire contents of each well were collected and trypsinized at
37°C with gentle agitation every 10 min until aggregates were no longer visible (10-30 min).
Trypsin was inactivated and Trypan Blue Exclusion cell counting was performed using a TC10
Automated Cell Counter (Bio-Rad). For long-term spheroid growth assays, cells were seeded
into a 96-well round-bottom ULA plate at a density of 2000 cells/well. Phase-contrast images
were captured at 2-hour intervals for up to 12 days using the IncuCyte Zoom imaging platform.
Single spheroids were isolated at specific time points post-seeding (3, 7, 14, and 21 days) and
transferred into separate wells of a 48-well adherent culture plate, incubated for 2 days, then
attached spheroids were fixed and stained using the Protocol Hema 3 staining kit (Fisher
Scientific).
Xenotransplantation assays
NOD/SCID female mice (8-10 weeks old; Charles River) were inoculated by intraperitoneal
injection with 150 µL of PBS containing the following numbers of cells: OVCAR8/OVCAR8STK11KO, 4 x 106; HeyA8/HeyA8-STK11KO, 1 x 106; iOvCa147/iOvCa147-STK11KO, 2 x 106.
For survival analyses (OVCAR8, OVCAR8-STK11KO, HeyA8, HeyA8-STK11KO, iOvCa147
and iOvCa147-STK11KO cells), mice were monitored daily after intraperitoneal injection and
euthanized using standard criteria for humane endpoints (i.e., lethargy, hunched posture,
impaired breathing, extreme weight loss, excessive ascites). Mice were provided chow (cat. no.
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2919, Envigo) and water ad libitum throughout the study. All animal experiments were approved
by Institutional Animal Care and Use Committee of the University of Western Ontario and
carried out in accordance with the approved guidelines.
Inhibition of CAMKK2
Cells were seeded into a 6-well adherent culture plate, and treatment was initiated the following
day with 10 μM STO-609 or an equivalent volume of DMSO. For analysis of spheroids, cells
were seeded into a 6-well ULA plate and treated with 10 μM STO-609 or DMSO at the time of
seeding. Lysates were generated for immunoblot analysis at 24 h (FT190, FT190-STK11KO,
iOvCa147 and iOvCa147-STK11KO cells) or 72 h (OVCAR8 and OVCAR8-STK11KO cells).
Induction of metabolic stress
For glucose deprivation experiments, cells were seeded into 96-well adherent culture plates
(2500 cells/well) in complete growth medium. The following day, growth medium was aspirated,
washed once with serum- and glucose-free medium, and replaced with medium containing 10%
dialyzed FBS (Invitrogen) and 0.1 g/L glucose. For serum deprivation experiments, cells were
incubated with medium containing 0.25% FBS. For inhibition of mitochondrial complex V using
oligomycin A or pharmacological activation of AMPKα using AICAR, cells were seeded into
96-well adherent culture plates (1000 cells/well) in complete growth medium in a volume of 150
μL. The following day, 50 μL of complete growth medium containing oligomycin, AICAR, or
vehicle (DMSO) was added to each well. Viability was assessed 72 h later using the CyQuant
Cell Proliferation assay as per manufacturer’s instructions.
Reverse phase protein array (RPPA) analysis
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Adherent cells were harvested at 24 h and 72 h post-seeding by trypsinization followed by
addition of RPMI with 10% FBS; spheroids were directly collected from ULA plates at these
same time points. Cells were pelleted (800xg, 4°C) and washed twice in ice cold PBS, then flashfrozen on dry ice, and stored at -80°C until sample submission. RPPA analysis was performed by
the Functional Proteomics RPPA Core Facility at the MD Anderson Cancer Center according to
their

standard

protocol

[https://www.mdanderson.org/research/research-resources/core-

facilities/functional-proteomics-rppa-core/antibody-information-and-protocols.html].
Normalized data and log2-fold changes are summarized in Supplementary Table S2. A heat
map

was

generated

using

log2-fold

change

data

and

the

Matrix2png

interface

(https://matrix2png.msl.ubc.ca).
DUSP4 knockdown
Transfections were performed of cells seeded in 6-well plates using DharmaFECT1 as per
manufacturer's protocol (Dharmacon; Thermo Fisher Scientific Inc., Waltham, MA). DUSP4
(M-003963-03) and non-targeting control pool #2 (D-001206-14-05) siGENOME SMARTpool
siRNA was used. After 72 h, trypsinized cells were counted and seeded at a density of 5 × 104
cells per well in 24-well ULA cluster plates and 2 × 103 cells per well in 96-well round-bottom
ULA cluster plates. Cell viability was determined at 72 h post-seeding in 96-well round-bottom
ULA cluster plates using CellTiter-Glo® (Promega). Western blot analysis was performed on
adherent cell lysates at 72 h post-seeding to confirm DUSP4 knockdown.
Statistical analysis
All statistical analyses were performed using GraphPad Prism 6.05 (GraphPad Software, San
Diego, CA). The results from in vitro analyses were assessed using a two-tailed Student’s t-test
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or two-way ANOVA with Tukey’s multiple comparisons test. Tumour latency analysis in mice
was tested for significance using the log-rank test. In all cases, a p-value of less than 0.05 was
considered statistically significant.
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FIGURE LEGENDS
Figure 1. Loss of LKB1 reduces EOC cell anchorage-independent growth. (A) Immunoblot
analysis of FTE and EOC STK11KO cell lines and matched parental controls to confirm loss of
LKB1 protein expression in CRISPR/Cas9-edited lines. (B) Doubling time for parental and
STK11KO cell lines in adherent culture conditions. Confluence was monitored over 3 days in
adherent culture using the IncuCyte Zoom imaging system. Doubling time was determined using
GraphPad Prism 6.0 by fitting an exponential growth curve to confluence over time data in at
least 3 independent experiments. (C) Images of OVCAR8, OVCAR8-STK11KO, HeyA8 and
HeyA8-STK11KO cell lines cultured in soft agar to assess anchorage-independent colony
forming potential. Images are representative of 3 independent experiments. Scale bars represent
500 µm. (D) Quantification of soft agar colony formation. Data are presented as colony counts
per field of view and relative colony size within each independent experiment. Groups were
compared using the two-tailed Student’s t-test (**, p < 0.01; ***, p < 0.001).
Figure 2. LKB1 is required for EOC spheroid cell viability. (A) Images of FTE and EOC cell
lines cultured in suspension using ultra-low attachment (ULA) vessels. Images were captured at
the following time points (post-seeding): FT190, FT190-STK11KO, day 7; OVCAR8, OVCAR8STK11KO, day 5; HeyA8, HeyA8-STK11KO, iOvCa147, iOvCa147-STK11KO, day 3. Scale
bars represent 1 mm (upper panels) and 250 µm (lower panels). (B) Cell viability for FTE and
EOC cell lines cultured in suspension using ULA vessels. Viable and non-viable cell numbers
were determined by trypan blue exclusion cell counting in a minimum of 3 independent
experiments. Data are presented as the number of dead and viable cells per well of a 24-well
plate (mean ± SEM). Two-way ANOVA and Tukey’s multiple comparisons test were performed
for statistical analysis (*, p < 0.05; **, p < 0.01; ***, p < 0.001; ****, p < 0.0001). (C) LKB1 is
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required for long-term growth and viability of EOC spheroids. EOC cells were cultured in 96well round-bottom ULA plates to form single spheroids for the indicated time periods up to 21
days and phase contrast images were captured (upper panels, “suspension”). At each indicated
time point, individual spheroids were transferred to single wells of a 48-well adherent culture
plate for 1 day (HeyA8, HeyA8-STK11KO) or 2 days (OVCAR8, OVCAR8-STK11KO) for
sufficient re-attachment. Following transfer of spheroids into adherent culture, cells were fixed
and stained (lower panels, “reattached”). Scale bars represent 200 µm.
Figure 3. EOC cells lacking LKB1 have decreased metastatic potential. (A) Survival analysis for
parental and STK11KO EOC cell lines. EOC cells were injected i.p. into female NOD/SCID
mice. Mice were euthanized when humane endpoint criteria were reached. Censored subjects due
to thymic lymphoma in the iOvCa147/iOvCa147-STK11KO study are indicated by tick marks on
the survival curve. OVCAR8, OVCAR8-STK11KO, HeyA8, HeyA8-STK11KO, n=6 per group;
iOvCa147, iOvCa147-STK11KO, n=12 per group. Parental and STK11KO survival curves were
compared using the log-rank test. (B) Representative images of mice at time of necropsy.
Tumours are indicated by black arrows (OVCAR8 and iOvCa147) or enclosed within a dotted
black boundary (HeyA8). (C) Quantification of total tumour burden. Mice were euthanized at a
single time point post-injection (OVCAR8, OVCAR8-STK11KO, 51d; HeyA8, HeyA8STK11KO, 33d) and all macroscopically visible tumours were excised and weighed together.
Data are presented as the total tumour wet weight per mouse and the overall mean. Parental and
STK11KO groups were compared using the two-tailed Student’s t-test (*, p < 0.05). (D)
Immunoblot analysis on excised tumours to confirm absence of LKB1 in OVCAR8- and HeyA8STK11KO tumours. Tubulin was used as a loading control. Each lane represents a tumour from a
different mouse.
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Figure 4. Histopathologic differences due to LKB1 loss in xenografted EOC tumours. (A) Serial
sections were stained with hematoxylin and eosin (H&E), and immunostained using Ki67 for
proliferation and cleaved caspase-3 for apoptosis. Boxes (dashed black lines) in the left-hand
H&E panels at low magnification represent areas shown in the higher magnification panels to
their right. Scale bars represent 1 mm. (B) Immunoblot analysis to determine relative carbonic
anhydrase 9 (CA9) protein abundance as a marker of hypoxia in OVCAR8 and OVCAR8STK11KO xenograft tumours. Each lane represents a tumour from a different mouse. (C)
Densitometric analysis of immunoblot in (B). Data are presented as the pixel intensity volume
for CA9 normalized to tubulin. Groups were compared using the two-tailed Student’s t-test (*, p
< 0.05).
Figure 5. AMPKα phosphorylation is maintained in FTE and EOC STK11KO cells. (A)
Immunoblot analysis to assess p-AMPKα (T172) in parental and STK11KO FTE and EOC cell
lines cultured as adherent monolayers (adh) or spheroids in suspension (sph). LKB1 loss was
confirmed, and tubulin was used as a loading control. (B) Immunoblot analysis to assess pAMPKα (T172) in FTE, OVCAR8 and iOvCa147 cells cultured under adherent (adh) or
suspension (sph) conditions in the presence of 10 μM STO-609 or the equivalent concentration
(v/v) of DMSO (veh). (C) Immunoblot analysis to determine relative p-AMPKα (T172) levels in
xenograft tumours. LKB1 loss was confirmed, and vinculin was used as a loading control. Each
lane represents a tumour from a different mouse. (D) Densitometric analysis of immunoblots in
(A). Data are presented as the pixel intensity volume for p-AMPKα (T172) normalized to
AMPKα. Groups were compared using the two-tailed Student’s t-test with no significant
difference observed.
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Figure 6. DUSP4 expression is increased due to sustained LKB1 loss. (A) Lysates from
OVCAR8, OVCAR8-STK11KO, HeyA8 and HeyA8-STK11KO cells grown in adherent and
spheroid culture were subjected to reverse-phase protein array analysis. Data is presented as a
heat map of the log2-transformed fold-change in expression comparing STK11KO cells to their
respective parental cell controls. DUSP4 expression was consistently increased due to LKB1 loss
in every sample analyzed. (B) Immunoblot analysis confirming DUSP4 expression is increased
in all three EOC cell lines lacking LKB1 as compared with their respective controls. (C)
Immunoblot analysis demonstrating increased DUSP4 protein in OVCAR8-STK11KO tumour
xenografts as compared with OVCAR8 tumours. LKB1 loss was confirmed, and tubulin used as
a loading control. (D) Densitometric analysis of immunoblots in (C). Data are presented as the
pixel intensity volume for DUSP4 normalized to tubulin with the mean value for OVCAR8
tumours set to 1. Statistical analysis was performed using a two-tailed Student’s t-test (*, p <
0.05). (E) Knockdown of DUSP4 in HeyA8 and HeyA8-STK11KO cells as confirmed by
immunoblot analysis. (F) Restoration of intact spheroid formation in HeyA8-STK11KO cells
resulting from DUSP4 knockdown. Scale bar represents 250 µm (G) Rescue of cell viability in
HeyA8-STK11KO spheroids due to DUSP4 knockdown as determined by Cell-Titer Glo assay in
a 96-well ULA format. Two-way ANOVA and Tukey’s multiple comparisons test was
performed (****, p < 0.0001).
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